Analysts have been eager to weigh in on the Healthcare sector with new ratings on Neurocrine (NBIX – Research Report), HealthStream (HSTM – Research Report) and Vertex Pharmaceuticals (VRTX – Research Report).
Neurocrine (NBIX)
Canaccord Genuity analyst Sumant Kulkarni maintained a Buy rating on Neurocrine yesterday and set a price target of $154.00. The company’s shares closed last Tuesday at $140.09, close to its 52-week high of $148.37.
According to TipRanks.com, Kulkarni is a 4-star analyst with an average return of
Currently, the analyst consensus on Neurocrine is a Moderate Buy with an average price target of $153.81, a 9.1% upside from current levels. In a report issued on April 11, Stifel Nicolaus also maintained a Buy rating on the stock with a $165.00 price target.
See the top stocks recommended by analysts >>
HealthStream (HSTM)
In a report released yesterday, Richard Close from Canaccord Genuity maintained a Hold rating on HealthStream, with a price target of $27.00. The company’s shares closed last Tuesday at $26.41.
According to TipRanks.com, Close is a 5-star analyst with an average return of
Currently, the analyst consensus on HealthStream is a Moderate Buy with an average price target of $33.00, implying a 34.1% upside from current levels. In a report released yesterday, JMP Securities also maintained a Hold rating on the stock.
Vertex Pharmaceuticals (VRTX)
Canaccord Genuity analyst Whitney Ijem maintained a Sell rating on Vertex Pharmaceuticals yesterday and set a price target of $371.00. The company’s shares closed last Tuesday at $404.91.
According to TipRanks.com, Ijem is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Vertex Pharmaceuticals with a $456.11 average price target, a 12.9% upside from current levels. In a report issued on April 11, Robert W. Baird also maintained a Sell rating on the stock with a $325.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on NBIX:
- Neurocrine’s NBI-1065845 shows efficacy in major depressive disorder
- Neurocrine, Sentia Medical Sciences extend CRF research collaboration
- Voyager announces selection of development candidate for GBA1 Program
- Neurocrine initiates Phase 1 study of NBI-1065890
- Neurocrine price target raised to $158 from $148 at JPMorgan